Combined glucocorticoid and antiviral therapy of hepatitis B virus-related liver failure
Related Experiment Video
Updated: Apr 16, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
Jan-Hendrik Bockmann1, Maura Dandri1, Stefan Lüth1
1Jan-Hendrik Bockmann, Maura Dandri, Stefan Lüth, Nadine Pannicke, Ansgar W Lohse, 1 Deparment of Medicine, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
Abstract:
Acute hepatic failure due to hepatitis B virus (HBV) can occur both during primary infection as well as after reactivation of chronic infection. Guidelines recommend considering antiviral therapy in both situations, although evidence supporting this recommendation is weak. Since HBV is not directly cytopathic, the mechanism leading to fulminant hepatitis B is thought to be primarily immune-mediated. Therefore, immunosuppression combined with antiviral therapy might be a preferred therapeutic intervention in acute liver failure in hepatitis B. Here we report our favourable experience in three hepatitis B patients with fulminant hepatic failure who were treated by combining high-dose steroid therapy with standard antiviral treatment, which resulted in a rapid improvement of clinical and liver parameters.
More Related Videos
Related Concept Videos
Hepatitis
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Retrovirus Life Cycles
Inhibitors of Viral Protein Synthesis

